Curated News
By: NewsRamp Editorial Staff
July 27, 2026
VERAXA Biotech Advances Bispecific ADC Program with OmniAb
TLDR
- VERAXA's VXA-222 advances in solid tumor treatment, targeting two antigens for precision, potentially offering a competitive edge in oncology.
- OmniAb's discovery platform and VERAXA's linker technology collaborate to develop VXA-222, an AND-gate bispecific ADC entering next phase.
- VXA-222 aims to improve precision in treating solid tumors, potentially reducing side effects and advancing cancer care for patients.
- VXA-222 uses an AND-gate approach to target two tumor antigens simultaneously, a novel strategy to enhance cancer therapy specificity.
Impact - Why it Matters
This news matters because it represents a step forward in precision oncology. The 'AND-gate' approach of VXA-222 could reduce off-target effects and improve outcomes for patients with solid tumors, addressing a significant unmet need. The collaboration between VERAXA and OmniAb exemplifies how combining complementary technologies can accelerate the development of more effective cancer therapies, potentially leading to new treatment options and improved quality of life for patients.
Summary
LOS ANGELES, CA - July 27, 2026 - VERAXA Biotech (NASDAQ: VRXA) has announced a significant milestone in its collaboration with OmniAb, advancing its bispecific antibody-drug conjugate (bsADC) program, VXA-222. OmniAb successfully completed its discovery work, enabling the program to transition to the next phase. VXA-222 employs an innovative “AND-gate” approach to target two tumor antigens with a single molecule, aiming to enhance precision in treating solid tumors. This milestone underscores the progress in developing next-generation cancer therapies that could offer more targeted and effective treatments.
Under the collaboration initiated in May 2025, OmniAb utilized its antibody discovery technologies, including the OmniClic™ platform, while VERAXA contributed its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products from the collaboration, with OmniAb receiving a share of specified revenue from resulting products. This partnership leverages OmniAb's discovery capabilities and VERAXA's specialized delivery technologies to create a potentially more precise cancer therapy.
VERAXA is focused on building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company’s pipeline, driven by quality-by-design principles, aims to advance ADCs and proprietary BiTAC® formats into clinical development. VERAXA was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a renowned institution in life science research. The advancement of VXA-222 marks a critical step toward potentially offering new treatment options for patients with solid tumors, highlighting the importance of collaborative innovation in biotechnology.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, VERAXA Biotech Advances Bispecific ADC Program with OmniAb
